Genetic Polymorphism of ERCC1 and XRCC1 Correlated with Response to Oxaliplatin Based Chemotherapy in Advanced Colorectal Cancer

梁军,吕红英,张克,梁华

DOI: https://doi.org/10.3969/j.issn.1000-8179.2008.18.015

2008-01-01

Abstract:OBJECTIVE:To assess whether the polymorphism of ERCC1 Asn118Asn and XRCC1 Arg399Gln has an effect on the clinical outcome in Chinese patients treated with oxaliplatin as first-line chemotherapy regimens for advanced colorectal cancer.METHODS:DNA was extracted from peripheral venous blood before chemotherapy in 62 advanced colorectal cancer patients.Real-time PCR was used for genotyping the SNP of ERCC1 and XRCC1.The patients were routinely treated with oxaliplatin-based chemotherapy.The relationship between objective tumor response(OR)and genotypes was studied.RESULTS:ERCC1 Asn118Asn had three allelotypes in this group and their frequencies were C/C 53.23%(33/62),C/T 37.10%(23/62),T/T 9.67%(6/62)respectively.The fregnoncies of XRCC1 Arg399Gln were G/G 50.00%(31/62),G/A 37.10%(23/62),A/A 12.90%(8/62)respectively.The clinical benifit rate for 62 stage Ⅳ cases was 54.84%,including 0 CR,18 PR,16 SD,28 PD calculated after 2 or 3 cycles.The patients with C/C genotype showed distinctly preponderance compared to those with C/T+T/T,and there was a statistically difference between the clinical benifit group(CR+PR+SD)and un-response group PD,χ2=6.289,P=0.021,and so was XRCC1 Arg399Gln G/G and G/A+A/A,χ2=6.513,P=0.021.In addition,these two polymorphisms seemed to have synergic effect,with OR being 11.333(P=0.002)for patients carrying the ERCC1 C/C and XRCC1 G/G genotypes compared with those carrying the ERCC1 C/T+T/T and XRCC1 G/A+A/A genotypes.CONCLUSION:ERCC1 Asn118Asn and XRCC1 Arg399Gln genetic polymorphisms may be associated with clinical outcomes of Chinese patients with advanced colorectal cancer accepted oxaliplatin as first-line.